{"ticker": {"uuid": "86d43ae4-2c47-4e42-9042-b090168def40", "symbol": "HELP", "name": "Cybin Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Library helping teachers stock up their classrooms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPM2pJMVZ1RlZPVk8tN0hDQXRfVkVWcXJZLVlFVi1EdklBbkZiM29sZTVteWJ6ZV9pRzN4R29RQVYyZjdhanhtMEQ2Zml0Q3R4SC15X29VTkl0OTBHQmFTU01JQzVUM19KQTFLNVNoem5Hc0tsNDdWRFZyZnh0NnRMb3NwbWFjVGNBZTJj0gGfAUFVX3lxTE8wYzZkQy1jMEFDV3RMTDA3VDB0LWpXWHlwNXRkSGhOZ21oQ0w3TTFBdWFUNDlHRER5d01zRzB4XzlWMG1sS0ltTFBDMkszbDRqUXRObmVBVFltbDZ6UHFDSm9PV0o3Z0R6RDhwUk11dy1sd0dKTF9zd1hJS0ZwQl80M2c0RUx4d1JQZHFrb0xZakloZTRBc3R6MXlZQUdDOA?oc=5", "source_name": "WTVA", "published_at": "2026-07-15T23:19:00+00:00", "published_display": "15 Jul 2026 23:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Tightens Range As Traders Watch Support", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQZ2lhVUttODNsSGpBR3pQd040TjNfVzk4WVV2RmVWdjk5dzNtMzd5MGJaOGFQdllXWHpjbVo5MDJLSUFkRjdGZmY5bVdjRlZ1ZHlsdEc5WklvYmRMbEtGVHhOVjZZRkRKVzNwc0JGdnBIVy13TEFmUWdoRkZ2OFQ0cFVJdw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-07-15T18:03:00+00:00", "published_display": "15 Jul 2026 18:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inflation Optimism Helps Restore Stock Market Sentiment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOVzhpNkdkN3FHMFcteE9GSEh0OERBMTNBZl94TjF2WXJxaWxIYlowX29tUkpCOXI2RGdKNUVhOFZiZHdzMnNQYl80amU5bmNMSWJFZGlranJ1M1VZNGk3aEdPTEhKdFliS0tvQlNsVmUyS1ZCQ192THhjOXJWdElhZEI3MVRIbG9WTHE4alhiNkc0Rkdmbm82R2E1Y0psS2lWcDdNWmNNNklpWXZpbDNfWks4R3UxYVU?oc=5", "source_name": "Schaeffer's Investment Research", "published_at": "2026-07-15T16:06:15+00:00", "published_display": "15 Jul 2026 16:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOajNsVmM3Z3M5MkhkemVYSndDQzBveFJ3ZWdDSnpLUVNIYWN6UjRtUUlWV1JpSU81OG50NmdXcWxuYkw3T3NKaTc4bmt2c1ZMT1RtbUxBekp1SXVjdklxNGhWekJILXZuSGw4azB5LUVmeFE5ckJPam5fOGxqWEpQVElFakF3MWRfRFpZ?oc=5", "source_name": "Market source", "published_at": "2026-07-15T09:22:13+00:00", "published_display": "15 Jul 2026 09:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFAwMGtPT2huOERzcXlCQ2RHZjg2SERwbzBNSUM2T0pZWWJzb2pPNDRtMUd2ck1wdVR6Z2VxSGhDTFNIeTU4dGNHMDlncVp5NGtm?oc=5", "source_name": "CNN", "published_at": "2026-07-15T03:25:36+00:00", "published_display": "15 Jul 2026 03:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This $69 AI Stock Tool Helps Entrepreneurs Save Time on Market Research", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQOE1aRjRBSG9WSUpWc095QWp6UElreUJtYWFwQUFGdF9ibTk3WHZBbEJ5ME1saF8wX0cwamdhM3hxYmpfdC1QdWp6RnhLZXVhMUtPQUUtT1dmLWhYZ2Q4QXRvWm1EMHdjWTBBNElzdFhGaWE0TnhXZEYzUmptSjJVSl93a0N5c3ltRmhCRDFtVUtwUUxDaTZYaTktc1E4ZzRsNUFKdUZfdw?oc=5", "source_name": "entrepreneur.com", "published_at": "2026-07-15T03:01:55+00:00", "published_display": "15 Jul 2026 03:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Finding Solutions: Stock the Classroom helps local teachers prepare for students this fall", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOV0lBbFFFZVUwcUNtX1dsSWhxRU92MnpWY2h3UWhlTFhIYXFEbUtLUUJyeFVoLVhxX3gtQnVzb1pwT2FyMkV2OXB0YUo5U194SW8tWVFEMWh4TkZ3N2dnTDg2UzkzMlhHdU5ZNXJIVnA1TlpLdEZibkVOR09xMk5xUGU0R21POGNzb2JvWm1aR2dZU0JrWWhETHdTaXdFeUFEWFZobUVadU05ZDR3NV9Ncmp4OGPSAcgBQVVfeXFMT3N1REp1dms3N0RsXy02b1V3Y212M0x1RjBndTQ2MWZnREI0U1ZwMWFxaDgwR2t6eGFKbDF5M3FuS3lqWmhyc1VScTR3aHBSUlRQMHB4WDRObXAyaE8xZmpvdXkxVUJyY1dHZUVVNnBpak9aR1hXbVh5VzJEV0JwYkVLb29LVGx4UUQzanhYQnp1aWZ6dnItTTQzRnFQUXNXNTJLSTl0RkxTR3kzeWNnOVRJUnktLVlXZW9lUHphVkJ0UHR5SllyM2g?oc=5", "source_name": "WRDW", "published_at": "2026-07-14T21:58:00+00:00", "published_display": "14 Jul 2026 21:58", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three Price Target Boosts Can\u2019t Help Tesla Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTFB2R2p2UVEya2ZoSHNFZmpKdTQ0QW5BQ2RGWmxtYlR2aldBM0g1akRSSkJGTVFDWWhnMTNheTllcHhoTVoxR183bEswaE5yd3Bqcl9laFJZRXB3RFQ2V3RxV2VMOEhTcHNackJYc2dhQ1VQUnF5?oc=5", "source_name": "Barron's", "published_at": "2026-07-14T20:23:00+00:00", "published_display": "14 Jul 2026 20:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vail says luxury experiences will help growth amid falling stock price", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPdEpLVVNuZWlQUFNwTmFabWx5VVBTTHdLSFJJTjJvUHhSZ2VzOXdjbjhvd1c1cGRkV1pqVnBTTnNIc1plVTRLZFpPQlpQQWhBZjlYZld2cmh5eG9BdTFCTHN4bkJHdWxQb2Y2c1V0ME80Wkpab1YyY3d0UlhKWHpjMV9oZWs1VGR1R2c3WXBGZDVJWWM4THNnZDZCRGZYc1U0dTMwZg?oc=5", "source_name": "KPCW", "published_at": "2026-07-14T18:01:00+00:00", "published_display": "14 Jul 2026 18:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CVS Health (CVS) Expands GLP 1 Support, Does The Stock Look Fully Valued?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPOEFnQXdfdnBLZFhHYTFPWmZqVzM0OWlyRm1qMDg5M0FtcVlROW8xRGRLcjUtdl94blF0R1NWS1pRQm9SN0xoV1BNSk1ySTFxSjlfMHNQbGVsdkNfSkZCVlVvOUw0elJaMFlQM0xMOGR3d3ZyVE50NEszc2Y0VDl5N1dTQkJpYjhUdU1oMmpqNTRNY2J1UGc?oc=5", "source_name": "Market source", "published_at": "2026-07-14T16:12:58+00:00", "published_display": "14 Jul 2026 16:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A streaming stock risks diving below its key support level this week. Here's what else Jay Woods is watching", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOdl9TRVBtS1Z6d0ZjSUtZeEFkT1puRzdkVENrZC1VcVpyeVB6ampmRDNUTlJvTFgwNTdqNTBzWUx0TUtPaGhTUkJYcl8xamFRbUd0eXo2SFFZMmFYb2w4SWROVHhpXzJsZjdQdzhhUVJyZk9jQ0ZsdndvXzBRMkczdWZCV3laY1g4SkNDM2p4NlBfU1NLazdxSENUQi15Y1ZmWklNS0JQZjBQUQ?oc=5", "source_name": "CNBC", "published_at": "2026-07-13T19:03:58+00:00", "published_display": "13 Jul 2026 19:03", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How AI Is Helping to Explain Stock-Price Moves", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPY3c1cXE0NFhNX0R0Z3NSUkExUWZYdnUyMlFpcmtjSk5qQ2FObnBKVi1CT0JKNS03X1I4bGJEOWlNS3BHeDlOdHRYb0VYTHlKVkZ1d1M0aGZjME9hcEplNU1UNUFYZGdLTkRpanJ3ZjVRZlg5bTQzRnhVZzBZUjlnWGFIOEg3d0pIa3BjOWEyNkt1V2c?oc=5", "source_name": "The University of Chicago Booth School of Business", "published_at": "2026-07-13T17:30:36+00:00", "published_display": "13 Jul 2026 17:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer Highlights the Strong Institutional Support for Welltower Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNXFQQW5xblhqTlhIQnI3bkhHU3Awa2I4Y0ZZNE03cDhmUE4zUVBwSnRoRzFzMmI3UV9wRHVZZWJ0X1lNaGs0RXF0cDhOSncya0lqbXFGVWF0UlU0Q3NzVmN0aXFjZ3B3UUFRQ0YteURKQnJsVVpHcUtWeUhlY1c3MXpkbExvdFJJOG5WOEswUWxkOHc2aHNjWFVsa21qSVpNSTVnNDFSV1h6OXM?oc=5", "source_name": "Market source", "published_at": "2026-07-13T15:26:10+00:00", "published_display": "13 Jul 2026 15:26", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Over 2/3 of Americans Support Bernie Sanders-Style AI Stock Ownership Plan, Poll Shows", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOTUVfdHJuN1RySG9BaTFHbzd3RkVLNGUtdldaTkpaZDBlSVdsSURnejI2TUJjdFdlOE1wUjh5YS1WeHRrZk5mSlFJYlpGYV9XZlBJYnd0cDE0aHFTTjd3Si03WXl4NDJOUE9TVTRNaEk3TEw4cVVPUWpRTktXX05Wa0EtcTB3U2U5RzhUTGgzUjcyaTIyTmZiUjI1MktaY3M4NVJvZ0dXRmluazdsT3RnbjdfZ0p6UlE?oc=5", "source_name": "Gizmodo", "published_at": "2026-07-13T09:00:47+00:00", "published_display": "13 Jul 2026 09:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Cybin(HELP.US) With Buy Rating, Cuts Target Price to $42", "summary": "CCORF has reiterated its Buy rating for Cybin (HELP.US)", "url": "https://www.moomoo.com/news/post/72375764/ccorf-maintains-cybin-helpus-with-buy-rating-cuts-target-price", "source_name": "Moomoo", "published_at": "2026-07-02T15:11:13", "published_display": "02 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc reports results for the quarter ended March 31 - Earnings Summary", "summary": "Cybin Inc. has reported its earnings results for the quarter that ended on March 31. This brief article from Reuters provides a summary of those financial results.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N4311WE:0-cybin-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/", "source_name": "TradingView", "published_at": "2026-06-30T00:39:13", "published_display": "30 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma (Nasdaq: HELP) funds late-stage CNS trials with $50M raise", "summary": "Helus Pharma (Cybin Inc.) reported audited fiscal 2026 results and significant pipeline progress, including a recent $50 million underwritten offering to fund its late-stage CNS programs. The company's cash balance stood at $157.3 million as of March 31, 2026, despite a widened n", "url": "https://www.stocktitan.net/sec-filings/HELP/6-k-cybin-inc-current-report-foreign-issuer-edfa3a182cc3.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:39:13", "published_display": "29 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc. (HELP) Form 40-F: 51.63M shares, governance disclosures", "summary": "Cybin Inc. filed its Annual Report on Form 40-F for the fiscal year ended March 31, 2026, reporting 51,631,804 common shares outstanding and confirming its status as a foreign private issuer and emerging growth company listed on Nasdaq under the symbol HELP. The report includes d", "url": "https://www.stocktitan.net/sec-filings/HELP/40-f-cybin-inc-annual-report-canadian-issuer-a5fcfea39e90.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:37:12", "published_display": "29 Jun 2026 11:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds", "summary": "Cybin (HELP) has seen its share price rebound recently after reporting that enrollment in its APPROACH Phase 3 trial for HLP003 in major depressive disorder has surpassed 86%. Despite this short-term improvement, the stock is still down significantly year-to-date and over five ye", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-as-phase-3-enrollment-progresses-the-undervalued", "source_name": "Simply Wall Street", "published_at": "2026-06-28T19:09:26", "published_display": "28 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Cybin Inc. (CYBN) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Cybin Inc. (CYBN) following a significant drop in stock price. This investigation comes after the announcement that CEO Doug Drysdale would be stepping down. The firm encourages stockh", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-cybin-inc-cybn-and-encourages", "source_name": "The National Law Review", "published_at": "2026-06-28T16:11:12", "published_display": "28 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Cybin, Inc. \u2013 NEO:HELP", "summary": "This page provides financial information for Cybin, Inc. (NEO:HELP), with a specific focus on its enterprise value to EBITDA forward metric. It also lists various TradingView features and services related to market data, analysis tools, and community engagement.", "url": "https://www.tradingview.com/symbols/NEO-HELP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:40:45", "published_display": "27 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cybin, Inc. \u2013 MUN:R7E", "summary": "This article provides financial information for Cybin, Inc. (R7E) on the Munich Stock Exchange, specifically focusing on its forward price-to-sales ratio. It indicates that the market is currently closed with no trades recorded.", "url": "https://www.tradingview.com/symbols/MUN-R7E/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:11", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc expected to post a loss of 93 cents a share - Earnings Preview", "summary": "Cybin Inc. is projected to report a loss of 93 cents per share. This information is provided as an earnings preview by Refinitiv. The article is a concise report highlighting upcoming financial expectations for the company.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N42Y1LT:0-cybin-inc-expected-to-post-a-loss-of-93-cents-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:11", "published_display": "26 Jun 2026 19:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?", "summary": "Cybin's investment narrative is re-evaluated following two key developments: Helus Pharma's HLP003 Phase 3 trial for major depressive disorder surpassing 86% enrollment, and Cybin Inc. completing a US$50 million equity raise. These events highlight clinical progress and near-term", "url": "https://finance.yahoo.com/healthcare/articles/cybin-help-28-9-phase-220929014.html", "source_name": "Market source", "published_at": "2026-06-26T19:09:28", "published_display": "26 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin (HELP) Is Up 28.9% After HLP003 Phase 3 Enrollment Surpasses 86% in MDD Trial", "summary": "Cybin's stock (HELP) surged 28.9% following an announcement that enrollment for its HLP003 Phase 3 trial for Major Depressive Disorder has surpassed 86%. This progress is significant for the company's investment narrative, which relies on the approval and adoption of psychedelic-", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-is-up-289-after-hlp003-phase-3-enrollment-surpass/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-26T12:40:11", "published_display": "26 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma\u2122 Announces Closing of US$50 Million Underwritten Offering - Thu, 06/25/2026 - 09:28", "summary": "Helus Pharma\u2122 has completed its previously announced underwritten offering, raising US$50 million through the sale of 10,309,280 common shares at US$4.85 each. The pharmaceutical company intends to utilize these net proceeds to advance its clinical programs, HLP003, HLP004, and H", "url": "https://ir.helus.com/news-releases/news-release-details/helus-pharmatm-announces-closing-us50-million-underwritten", "source_name": "Helus Pharma", "published_at": "2026-06-25T17:40:07", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma (Nasdaq: HELP) raises US$50M to fund NSA pipeline", "summary": "Helus Pharma, operating as Cybin Inc., successfully closed an underwritten offering, raising US$50 million through the sale of 10,309,280 common shares at US$4.85 per share. The company plans to allocate the net proceeds to advance its novel serotonergic agonist (NSA) pipeline, s", "url": "https://www.stocktitan.net/sec-filings/HELP/6-k-cybin-inc-current-report-foreign-issuer-42a6477e0dd3.html", "source_name": "Stock Titan", "published_at": "2026-06-25T15:12:15", "published_display": "25 Jun 2026 15:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma\u2122 Announces Closing of US$50 Million Underwritten Offering", "summary": "Helus Pharma\u2122 has completed its US$50 million underwritten offering of 10,309,280 common shares at US$4.85 per share. The proceeds will fund the development of its HLP003, HLP004, and HLP005 programs for major depressive disorder and generalized anxiety disorder, and for general ", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317639/0/en/helus-pharma-announces-closing-of-us-50-million-underwritten-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T13:12:15", "published_display": "25 Jun 2026 13:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma (HELP) prices US$50M share sale to fund Phase 3 MDD trial", "summary": "Helus Pharma, operating as Cybin Inc., has priced a US$50 million underwritten equity offering, selling 10,309,280 common shares at US$4.85 each. The proceeds will primarily fund its Phase 3 trial for HLP003 in Major Depressive Disorder (MDD) and other programs. The company also ", "url": "https://www.stocktitan.net/sec-filings/HELP/6-k-cybin-inc-current-report-foreign-issuer-d84abf281c2f.html", "source_name": "Stock Titan", "published_at": "2026-06-25T10:12:15", "published_display": "25 Jun 2026 10:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma\u2122 Announces US$50 Million Underwritten Offering", "summary": "Helus Pharma\u2122 announced the pricing of an underwritten offering of 10,309,280 common shares at US$4.85 per share, aiming to raise US$50 million in gross proceeds. The funds will primarily support the progression of its HLP003, HLP004, and HLP005 programs for major depressive diso", "url": "https://www.globenewswire.com/news-release/2026/06/24/3316649/0/en/helus-pharma-announces-us-50-million-underwritten-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T22:10:06", "published_display": "24 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc (CYBN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Cybin Inc (CYBN), noting its current stock price momentum score of 8.90 within the Biotechnology & Medical Research industry. It highlights the stock trading between a resistance level of 9.73 and a support level of 6.22, making it su", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cybn/technical", "source_name": "TradingKey", "published_at": "2026-06-19T18:10:15", "published_display": "19 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc (CYBN) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" overview for Cybin Inc (CYBN), detailing the shares held and percentage change by various institutional investors as of January 2, 2026. Key holders include Point72 Asset Management, OrbiMed Advisors, and VR Adviser, among other", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cybn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:37", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc (CYBN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Cybin Inc. (CYBN) has an earnings forecast score of 8.29, ranking 143 out of 403 in the Biotechnology & Medical Research industry, with an average analyst price target of $51.50 and a high of $114.00. Based on predictions from 9 analysts, the stock holds a \"Buy\" rating. Recent EP", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cybn/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:37", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc (CYBN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Cybin Inc (CYBN), ranking it 117th out of 403 companies in the Biotechnology & Medical Research industry with a financial score of 7.45. While its financial status is considered robust, the company's operating efficiency is low. Key f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cybn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T23:38:59", "published_display": "17 Jun 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma (Nasdaq: CYBN) to speak at H.C. Wainwright Neuro Perspectives", "summary": "Helus Pharma (commercial operating name of Cybin Inc.) will participate in the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15-16, 2026, with its Chief Medical Officer joining an on-demand fireside chat. The company, a clinical-stage pharmaceutical firm", "url": "https://www.stocktitan.net/sec-filings/CYBN/6-k-cybin-inc-current-report-foreign-issuer-79ea786e29c0.html", "source_name": "Stock Titan", "published_at": "2026-06-11T18:40:20", "published_display": "11 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma medical chief in June 15 neuro conference chat", "summary": "Helus Pharma (Nasdaq: HELP) Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15-16, 2026. The chat will be available on-demand starting June 15, 2026, at 7:00 a.m. EDT. Helus Ph", "url": "https://www.stocktitan.net/news/HELP/helus-pharma-to-participate-in-the-h-c-wainwright-7th-annual-neuro-hwck9813ic4e.html", "source_name": "Stock Titan", "published_at": "2026-06-11T11:39:33", "published_display": "11 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin (CYBN) showcases Helus Pharma at Jefferies Global Healthcare Conference", "summary": "Cybin Inc., operating as Helus Pharma, announced that its Interim CEO, Eric So, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026. The company is a clinical-stage pharmaceutical firm developing novel serotonergic agonist", "url": "https://www.stocktitan.net/sec-filings/CYBN/6-k-cybin-inc-current-report-foreign-issuer-5108543a939a.html", "source_name": "Stock Titan", "published_at": "2026-06-01T21:38:49", "published_display": "01 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HELP Should I Buy", "summary": "Intellectia AI analyzes whether investors should buy Cybin Inc. (HELP) stock, concluding it is not a good buy for beginner long-term investors due to weak technicals, lack of confirmed buy signals, and insufficient recent news or financial data. While there's a constructive analy", "url": "https://intellectia.ai/en/stock/HELP/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-05-22T08:39:16", "published_display": "22 May 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Point72 / Cohen disclose 686,669 shares in Cybin (CYBN)", "summary": "Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen have disclosed beneficial ownership of 686,669 Common Shares, representing 1.4% of Cybin Inc. (CYBN), as of March 31, 2026. This ownership, detailed in an amended Schedule 13G/A filing, includes 666,985 ", "url": "https://www.stocktitan.net/sec-filings/CYBN/schedule-13g-a-cybin-inc-amended-passive-investment-disclosure-40a1fc15e7d3.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:09:10", "published_display": "15 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Library helping teachers stock up their classrooms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPM2pJMVZ1RlZPVk8tN0hDQXRfVkVWcXJZLVlFVi1EdklBbkZiM29sZTVteWJ6ZV9pRzN4R29RQVYyZjdhanhtMEQ2Zml0Q3R4SC15X29VTkl0OTBHQmFTU01JQzVUM19KQTFLNVNoem5Hc0tsNDdWRFZyZnh0NnRMb3NwbWFjVGNBZTJj0gGfAUFVX3lxTE8wYzZkQy1jMEFDV3RMTDA3VDB0LWpXWHlwNXRkSGhOZ21oQ0w3TTFBdWFUNDlHRER5d01zRzB4XzlWMG1sS0ltTFBDMkszbDRqUXRObmVBVFltbDZ6UHFDSm9PV0o3Z0R6RDhwUk11dy1sd0dKTF9zd1hJS0ZwQl80M2c0RUx4d1JQZHFrb0xZakloZTRBc3R6MXlZQUdDOA?oc=5", "source_name": "WTVA", "published_at": "2026-07-15T23:19:00+00:00", "published_display": "15 Jul 2026 23:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Tightens Range As Traders Watch Support", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQZ2lhVUttODNsSGpBR3pQd040TjNfVzk4WVV2RmVWdjk5dzNtMzd5MGJaOGFQdllXWHpjbVo5MDJLSUFkRjdGZmY5bVdjRlZ1ZHlsdEc5WklvYmRMbEtGVHhOVjZZRkRKVzNwc0JGdnBIVy13TEFmUWdoRkZ2OFQ0cFVJdw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-07-15T18:03:00+00:00", "published_display": "15 Jul 2026 18:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Inflation Optimism Helps Restore Stock Market Sentiment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOVzhpNkdkN3FHMFcteE9GSEh0OERBMTNBZl94TjF2WXJxaWxIYlowX29tUkpCOXI2RGdKNUVhOFZiZHdzMnNQYl80amU5bmNMSWJFZGlranJ1M1VZNGk3aEdPTEhKdFliS0tvQlNsVmUyS1ZCQ192THhjOXJWdElhZEI3MVRIbG9WTHE4alhiNkc0Rkdmbm82R2E1Y0psS2lWcDdNWmNNNklpWXZpbDNfWks4R3UxYVU?oc=5", "source_name": "Schaeffer's Investment Research", "published_at": "2026-07-15T16:06:15+00:00", "published_display": "15 Jul 2026 16:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOajNsVmM3Z3M5MkhkemVYSndDQzBveFJ3ZWdDSnpLUVNIYWN6UjRtUUlWV1JpSU81OG50NmdXcWxuYkw3T3NKaTc4bmt2c1ZMT1RtbUxBekp1SXVjdklxNGhWekJILXZuSGw4azB5LUVmeFE5ckJPam5fOGxqWEpQVElFakF3MWRfRFpZ?oc=5", "source_name": "Market source", "published_at": "2026-07-15T09:22:13+00:00", "published_display": "15 Jul 2026 09:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFAwMGtPT2huOERzcXlCQ2RHZjg2SERwbzBNSUM2T0pZWWJzb2pPNDRtMUd2ck1wdVR6Z2VxSGhDTFNIeTU4dGNHMDlncVp5NGtm?oc=5", "source_name": "CNN", "published_at": "2026-07-15T03:25:36+00:00", "published_display": "15 Jul 2026 03:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This $69 AI Stock Tool Helps Entrepreneurs Save Time on Market Research", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQOE1aRjRBSG9WSUpWc095QWp6UElreUJtYWFwQUFGdF9ibTk3WHZBbEJ5ME1saF8wX0cwamdhM3hxYmpfdC1QdWp6RnhLZXVhMUtPQUUtT1dmLWhYZ2Q4QXRvWm1EMHdjWTBBNElzdFhGaWE0TnhXZEYzUmptSjJVSl93a0N5c3ltRmhCRDFtVUtwUUxDaTZYaTktc1E4ZzRsNUFKdUZfdw?oc=5", "source_name": "entrepreneur.com", "published_at": "2026-07-15T03:01:55+00:00", "published_display": "15 Jul 2026 03:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Finding Solutions: Stock the Classroom helps local teachers prepare for students this fall", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "WRDW", "published_at": "2026-07-14T21:58:00+00:00", "published_display": "14 Jul 2026 21:58", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three Price Target Boosts Can\u2019t Help Tesla Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTFB2R2p2UVEya2ZoSHNFZmpKdTQ0QW5BQ2RGWmxtYlR2aldBM0g1akRSSkJGTVFDWWhnMTNheTllcHhoTVoxR183bEswaE5yd3Bqcl9laFJZRXB3RFQ2V3RxV2VMOEhTcHNackJYc2dhQ1VQUnF5?oc=5", "source_name": "Barron's", "published_at": "2026-07-14T20:23:00+00:00", "published_display": "14 Jul 2026 20:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vail says luxury experiences will help growth amid falling stock price", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPdEpLVVNuZWlQUFNwTmFabWx5VVBTTHdLSFJJTjJvUHhSZ2VzOXdjbjhvd1c1cGRkV1pqVnBTTnNIc1plVTRLZFpPQlpQQWhBZjlYZld2cmh5eG9BdTFCTHN4bkJHdWxQb2Y2c1V0ME80Wkpab1YyY3d0UlhKWHpjMV9oZWs1VGR1R2c3WXBGZDVJWWM4THNnZDZCRGZYc1U0dTMwZg?oc=5", "source_name": "KPCW", "published_at": "2026-07-14T18:01:00+00:00", "published_display": "14 Jul 2026 18:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CVS Health (CVS) Expands GLP 1 Support, Does The Stock Look Fully Valued?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPOEFnQXdfdnBLZFhHYTFPWmZqVzM0OWlyRm1qMDg5M0FtcVlROW8xRGRLcjUtdl94blF0R1NWS1pRQm9SN0xoV1BNSk1ySTFxSjlfMHNQbGVsdkNfSkZCVlVvOUw0elJaMFlQM0xMOGR3d3ZyVE50NEszc2Y0VDl5N1dTQkJpYjhUdU1oMmpqNTRNY2J1UGc?oc=5", "source_name": "Market source", "published_at": "2026-07-14T16:12:58+00:00", "published_display": "14 Jul 2026 16:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A streaming stock risks diving below its key support level this week. Here's what else Jay Woods is watching", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOdl9TRVBtS1Z6d0ZjSUtZeEFkT1puRzdkVENrZC1VcVpyeVB6ampmRDNUTlJvTFgwNTdqNTBzWUx0TUtPaGhTUkJYcl8xamFRbUd0eXo2SFFZMmFYb2w4SWROVHhpXzJsZjdQdzhhUVJyZk9jQ0ZsdndvXzBRMkczdWZCV3laY1g4SkNDM2p4NlBfU1NLazdxSENUQi15Y1ZmWklNS0JQZjBQUQ?oc=5", "source_name": "CNBC", "published_at": "2026-07-13T19:03:58+00:00", "published_display": "13 Jul 2026 19:03", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How AI Is Helping to Explain Stock-Price Moves", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPY3c1cXE0NFhNX0R0Z3NSUkExUWZYdnUyMlFpcmtjSk5qQ2FObnBKVi1CT0JKNS03X1I4bGJEOWlNS3BHeDlOdHRYb0VYTHlKVkZ1d1M0aGZjME9hcEplNU1UNUFYZGdLTkRpanJ3ZjVRZlg5bTQzRnhVZzBZUjlnWGFIOEg3d0pIa3BjOWEyNkt1V2c?oc=5", "source_name": "The University of Chicago Booth School of Business", "published_at": "2026-07-13T17:30:36+00:00", "published_display": "13 Jul 2026 17:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer Highlights the Strong Institutional Support for Welltower Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNXFQQW5xblhqTlhIQnI3bkhHU3Awa2I4Y0ZZNE03cDhmUE4zUVBwSnRoRzFzMmI3UV9wRHVZZWJ0X1lNaGs0RXF0cDhOSncya0lqbXFGVWF0UlU0Q3NzVmN0aXFjZ3B3UUFRQ0YteURKQnJsVVpHcUtWeUhlY1c3MXpkbExvdFJJOG5WOEswUWxkOHc2aHNjWFVsa21qSVpNSTVnNDFSV1h6OXM?oc=5", "source_name": "Market source", "published_at": "2026-07-13T15:26:10+00:00", "published_display": "13 Jul 2026 15:26", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Over 2/3 of Americans Support Bernie Sanders-Style AI Stock Ownership Plan, Poll Shows", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOTUVfdHJuN1RySG9BaTFHbzd3RkVLNGUtdldaTkpaZDBlSVdsSURnejI2TUJjdFdlOE1wUjh5YS1WeHRrZk5mSlFJYlpGYV9XZlBJYnd0cDE0aHFTTjd3Si03WXl4NDJOUE9TVTRNaEk3TEw4cVVPUWpRTktXX05Wa0EtcTB3U2U5RzhUTGgzUjcyaTIyTmZiUjI1MktaY3M4NVJvZ0dXRmluazdsT3RnbjdfZ0p6UlE?oc=5", "source_name": "Gizmodo", "published_at": "2026-07-13T09:00:47+00:00", "published_display": "13 Jul 2026 09:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Cybin(HELP.US) With Buy Rating, Cuts Target Price to $42", "summary": "CCORF has reiterated its Buy rating for Cybin (HELP.US)", "url": "https://www.moomoo.com/news/post/72375764/ccorf-maintains-cybin-helpus-with-buy-rating-cuts-target-price", "source_name": "Moomoo", "published_at": "2026-07-02T15:11:13", "published_display": "02 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc reports results for the quarter ended March 31 - Earnings Summary", "summary": "Cybin Inc. has reported its earnings results for the quarter that ended on March 31. This brief article from Reuters provides a summary of those financial results.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N4311WE:0-cybin-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/", "source_name": "TradingView", "published_at": "2026-06-30T00:39:13", "published_display": "30 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma (Nasdaq: HELP) funds late-stage CNS trials with $50M raise", "summary": "Helus Pharma (Cybin Inc.) reported audited fiscal 2026 results and significant pipeline progress, including a recent $50 million underwritten offering to fund its late-stage CNS programs. The company's cash balance stood at $157.3 million as of March 31, 2026, despite a widened n", "url": "https://www.stocktitan.net/sec-filings/HELP/6-k-cybin-inc-current-report-foreign-issuer-edfa3a182cc3.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:39:13", "published_display": "29 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc. (HELP) Form 40-F: 51.63M shares, governance disclosures", "summary": "Cybin Inc. filed its Annual Report on Form 40-F for the fiscal year ended March 31, 2026, reporting 51,631,804 common shares outstanding and confirming its status as a foreign private issuer and emerging growth company listed on Nasdaq under the symbol HELP. The report includes d", "url": "https://www.stocktitan.net/sec-filings/HELP/40-f-cybin-inc-annual-report-canadian-issuer-a5fcfea39e90.html", "source_name": "Stock Titan", "published_at": "2026-06-29T11:37:12", "published_display": "29 Jun 2026 11:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds", "summary": "Cybin (HELP) has seen its share price rebound recently after reporting that enrollment in its APPROACH Phase 3 trial for HLP003 in major depressive disorder has surpassed 86%. Despite this short-term improvement, the stock is still down significantly year-to-date and over five ye", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-as-phase-3-enrollment-progresses-the-undervalued", "source_name": "Simply Wall Street", "published_at": "2026-06-28T19:09:26", "published_display": "28 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Cybin Inc. (CYBN) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Cybin Inc. (CYBN) following a significant drop in stock price. This investigation comes after the announcement that CEO Doug Drysdale would be stepping down. The firm encourages stockh", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-cybin-inc-cybn-and-encourages", "source_name": "The National Law Review", "published_at": "2026-06-28T16:11:12", "published_display": "28 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Cybin, Inc. \u2013 NEO:HELP", "summary": "This page provides financial information for Cybin, Inc. (NEO:HELP), with a specific focus on its enterprise value to EBITDA forward metric. It also lists various TradingView features and services related to market data, analysis tools, and community engagement.", "url": "https://www.tradingview.com/symbols/NEO-HELP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:40:45", "published_display": "27 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cybin, Inc. \u2013 MUN:R7E", "summary": "This article provides financial information for Cybin, Inc. (R7E) on the Munich Stock Exchange, specifically focusing on its forward price-to-sales ratio. It indicates that the market is currently closed with no trades recorded.", "url": "https://www.tradingview.com/symbols/MUN-R7E/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:11", "published_display": "26 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc expected to post a loss of 93 cents a share - Earnings Preview", "summary": "Cybin Inc. is projected to report a loss of 93 cents per share. This information is provided as an earnings preview by Refinitiv. The article is a concise report highlighting upcoming financial expectations for the company.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N42Y1LT:0-cybin-inc-expected-to-post-a-loss-of-93-cents-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:11", "published_display": "26 Jun 2026 19:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity Raise - Has The Bull Case Changed?", "summary": "Cybin's investment narrative is re-evaluated following two key developments: Helus Pharma's HLP003 Phase 3 trial for major depressive disorder surpassing 86% enrollment, and Cybin Inc. completing a US$50 million equity raise. These events highlight clinical progress and near-term", "url": "https://finance.yahoo.com/healthcare/articles/cybin-help-28-9-phase-220929014.html", "source_name": "Market source", "published_at": "2026-06-26T19:09:28", "published_display": "26 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin (HELP) Is Up 28.9% After HLP003 Phase 3 Enrollment Surpasses 86% in MDD Trial", "summary": "Cybin's stock (HELP) surged 28.9% following an announcement that enrollment for its HLP003 Phase 3 trial for Major Depressive Disorder has surpassed 86%. This progress is significant for the company's investment narrative, which relies on the approval and adoption of psychedelic-", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-is-up-289-after-hlp003-phase-3-enrollment-surpass/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-26T12:40:11", "published_display": "26 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma\u2122 Announces Closing of US$50 Million Underwritten Offering - Thu, 06/25/2026 - 09:28", "summary": "Helus Pharma\u2122 has completed its previously announced underwritten offering, raising US$50 million through the sale of 10,309,280 common shares at US$4.85 each. The pharmaceutical company intends to utilize these net proceeds to advance its clinical programs, HLP003, HLP004, and H", "url": "https://ir.helus.com/news-releases/news-release-details/helus-pharmatm-announces-closing-us50-million-underwritten", "source_name": "Helus Pharma", "published_at": "2026-06-25T17:40:07", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma (Nasdaq: HELP) raises US$50M to fund NSA pipeline", "summary": "Helus Pharma, operating as Cybin Inc., successfully closed an underwritten offering, raising US$50 million through the sale of 10,309,280 common shares at US$4.85 per share. The company plans to allocate the net proceeds to advance its novel serotonergic agonist (NSA) pipeline, s", "url": "https://www.stocktitan.net/sec-filings/HELP/6-k-cybin-inc-current-report-foreign-issuer-42a6477e0dd3.html", "source_name": "Stock Titan", "published_at": "2026-06-25T15:12:15", "published_display": "25 Jun 2026 15:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma\u2122 Announces Closing of US$50 Million Underwritten Offering", "summary": "Helus Pharma\u2122 has completed its US$50 million underwritten offering of 10,309,280 common shares at US$4.85 per share. The proceeds will fund the development of its HLP003, HLP004, and HLP005 programs for major depressive disorder and generalized anxiety disorder, and for general ", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317639/0/en/helus-pharma-announces-closing-of-us-50-million-underwritten-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T13:12:15", "published_display": "25 Jun 2026 13:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma (HELP) prices US$50M share sale to fund Phase 3 MDD trial", "summary": "Helus Pharma, operating as Cybin Inc., has priced a US$50 million underwritten equity offering, selling 10,309,280 common shares at US$4.85 each. The proceeds will primarily fund its Phase 3 trial for HLP003 in Major Depressive Disorder (MDD) and other programs. The company also ", "url": "https://www.stocktitan.net/sec-filings/HELP/6-k-cybin-inc-current-report-foreign-issuer-d84abf281c2f.html", "source_name": "Stock Titan", "published_at": "2026-06-25T10:12:15", "published_display": "25 Jun 2026 10:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma\u2122 Announces US$50 Million Underwritten Offering", "summary": "Helus Pharma\u2122 announced the pricing of an underwritten offering of 10,309,280 common shares at US$4.85 per share, aiming to raise US$50 million in gross proceeds. The funds will primarily support the progression of its HLP003, HLP004, and HLP005 programs for major depressive diso", "url": "https://www.globenewswire.com/news-release/2026/06/24/3316649/0/en/helus-pharma-announces-us-50-million-underwritten-offering.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T22:10:06", "published_display": "24 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc (CYBN) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Cybin Inc (CYBN), noting its current stock price momentum score of 8.90 within the Biotechnology & Medical Research industry. It highlights the stock trading between a resistance level of 9.73 and a support level of 6.22, making it su", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cybn/technical", "source_name": "TradingKey", "published_at": "2026-06-19T18:10:15", "published_display": "19 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc (CYBN) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" overview for Cybin Inc (CYBN), detailing the shares held and percentage change by various institutional investors as of January 2, 2026. Key holders include Point72 Asset Management, OrbiMed Advisors, and VR Adviser, among other", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cybn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:37", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc (CYBN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Cybin Inc. (CYBN) has an earnings forecast score of 8.29, ranking 143 out of 403 in the Biotechnology & Medical Research industry, with an average analyst price target of $51.50 and a high of $114.00. Based on predictions from 9 analysts, the stock holds a \"Buy\" rating. Recent EP", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cybn/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:37", "published_display": "18 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin Inc (CYBN) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Cybin Inc (CYBN), ranking it 117th out of 403 companies in the Biotechnology & Medical Research industry with a financial score of 7.45. While its financial status is considered robust, the company's operating efficiency is low. Key f", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cybn/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T23:38:59", "published_display": "17 Jun 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma (Nasdaq: CYBN) to speak at H.C. Wainwright Neuro Perspectives", "summary": "Helus Pharma (commercial operating name of Cybin Inc.) will participate in the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15-16, 2026, with its Chief Medical Officer joining an on-demand fireside chat. The company, a clinical-stage pharmaceutical firm", "url": "https://www.stocktitan.net/sec-filings/CYBN/6-k-cybin-inc-current-report-foreign-issuer-79ea786e29c0.html", "source_name": "Stock Titan", "published_at": "2026-06-11T18:40:20", "published_display": "11 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Helus Pharma medical chief in June 15 neuro conference chat", "summary": "Helus Pharma (Nasdaq: HELP) Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15-16, 2026. The chat will be available on-demand starting June 15, 2026, at 7:00 a.m. EDT. Helus Ph", "url": "https://www.stocktitan.net/news/HELP/helus-pharma-to-participate-in-the-h-c-wainwright-7th-annual-neuro-hwck9813ic4e.html", "source_name": "Stock Titan", "published_at": "2026-06-11T11:39:33", "published_display": "11 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cybin (CYBN) showcases Helus Pharma at Jefferies Global Healthcare Conference", "summary": "Cybin Inc., operating as Helus Pharma, announced that its Interim CEO, Eric So, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026. The company is a clinical-stage pharmaceutical firm developing novel serotonergic agonist", "url": "https://www.stocktitan.net/sec-filings/CYBN/6-k-cybin-inc-current-report-foreign-issuer-5108543a939a.html", "source_name": "Stock Titan", "published_at": "2026-06-01T21:38:49", "published_display": "01 Jun 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HELP Should I Buy", "summary": "Intellectia AI analyzes whether investors should buy Cybin Inc. (HELP) stock, concluding it is not a good buy for beginner long-term investors due to weak technicals, lack of confirmed buy signals, and insufficient recent news or financial data. While there's a constructive analy", "url": "https://intellectia.ai/en/stock/HELP/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-05-22T08:39:16", "published_display": "22 May 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Point72 / Cohen disclose 686,669 shares in Cybin (CYBN)", "summary": "Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen have disclosed beneficial ownership of 686,669 Common Shares, representing 1.4% of Cybin Inc. (CYBN), as of March 31, 2026. This ownership, detailed in an amended Schedule 13G/A filing, includes 666,985 ", "url": "https://www.stocktitan.net/sec-filings/CYBN/schedule-13g-a-cybin-inc-amended-passive-investment-disclosure-40a1fc15e7d3.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:09:10", "published_display": "15 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 58, "sentiment_summary": {"positive": 18, "negative": 5, "neutral": 35, "score": 53, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 18.3, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 11.09, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 1.45, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 6.87, "latest_week": "2026-07-10", "one_week_move": 10.1, "four_week_move": 59.8, "twelve_week_move": 24.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.921087, "market_dynamics_buy_signal": false, "relative_strength": -5.897962, "fair_value_gap": -31.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.5592, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+10.1% over one week, +59.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "Barron's", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "Simply Wall Street", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+10.1% over one week, +59.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Library helping teachers stock up their classrooms"}], "updated_at": "2026-07-16T05:28:36.130283+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}